Table 1.
Baseline clinical characteristics of the study population.
| Control (n=30) | Dipper (n=30) | Non-dipper (n=30) | P for overall difference | |
|---|---|---|---|---|
| Age (years) | 53.2±15.4 | 52.5±15.1 | 54.6±13.0 | 0.858 |
| Men, n (%) | 12 (40) | 12 (40) | 11 (36.7) | 0.954 |
| Body mass index (kg/m2) | 28.8±4.6 | 28.8±4.5 | 28.9±4.3 | 0.993 |
| Smokers | 10 (33.3) | 7 (23.3) | 8 (26.7) | 0.679 |
| Clinical SBP (mmHg) | 126.3±8.8 | 144.5±15.9 | 148.2±21.8 | <0.001 |
| Clinical DBP (mmHg) | 75.5±9.1 | 83.4±12.3 | 83.7±13.3 | 0.012 |
| Total cholesterol (mg/dl) | 206.2±36.4 | 198.6±48.7 | 193.2±41.9 | 0.303 |
| Low-density lipoprotein (mg/dl) | 127.2±35.3 | 123.2±38.3 | 114.9±31.7 | 0.489 |
| High-density lipoprotein (mg/dl) | 48.8±10.1 | 44.8±10.6 | 44.7±11.7 | 0.258 |
| Triglycerides (mg/dl) | 161.2±67.0 | 144.7±57.2 | 132.8±68.5 | 0.120 |
| Creatinine (mg/dl) | 0.84±0.20 | 0.90±0.30 | 0.83±0.25 | 0.704 |
| Fasting glucose (mg/dl) | 102.0±13.7 | 101.3±15.4 | 98.9±10.6 | 0.766 |
| Hemoglobin (gr/dl) | 14.3±1.4 | 13.9±1.3 | 13.7±1.4 | 0.176 |
| White blood cell count (103/mm3) | 7.40±1.49 | 7.49±1.38 | 7.22±1.60 | 0.781 |
| Chemerin (ng/ml) | 85.4±38.1 | 182.4±21.4 | 219.7±16.3 | <0.001 |
| Medical treatments | ||||
| ACE inh. use (%) | 14 (46.7) | 12 (40.0) | 0.602 | |
| ARB use (%) | 7 (23.3) | 10 (33.3) | 0.390 | |
| Beta-blocker use (%) | 6 (20.0) | 10 (33.3) | 0.243 | |
| Ca-channel blocker use (%) | 8 (26.7) | 8 (26.7) | 1.000 | |
| Diuretic use (%) | 13 (43.3) | 12 (40.0) | 0.793 | |
SBP – systolic blood pressure; DBP – diastolic blood pressure; ACE inh. – angiotensin-converting-enzyme inhibitor; ARB – angiotensin receptor blocker.